All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @rebekitaoficial on TikTok ยท 7s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @rebekitaoficial's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00See you in the moonlight!

@rebekitaoficial's tirzepatide breakfast claims, fact-checked

๐Ÿ’โœจ๐“ก๐“ฎ๐“ซ๐“ฎโœจ๐Ÿ’

TikTok creator

432.6K viewsWatch on TikTok โ†’

Quick answer

Tirzepatide is a dual GLP-1/GIP receptor agonist administered as a once-weekly injection for type 2 diabetes and weight management. The SURMOUNT-1 trial demonstrated 22.5% weight loss with 15mg weekly dosing, but required extensive medical supervision due to significant gastrointestinal side effects.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @rebekitaoficial's tirzepatide breakfast claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@rebekitaoficial's tirzepatide breakfast claims, fact-checked" from ๐Ÿ’โœจ๐“ก๐“ฎ๐“ซ๐“ฎโœจ๐Ÿ’. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide is a dual GLP-1/GIP receptor agonist administered as a once-weekly injection for type 2 diabetes and weight management.

The reason this review is not generic is the source wording and the canonical claim label "glp1 tirz de desayuno almuerzo y cena si me dejan comienza ho." In this clip, the useful excerpt is: "See you in the moonlight!" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

SURMOUNT-1 trial showed 22.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide is a dual GLP-1/GIP receptor agonist administered as a once-weekly injection for type 2 diabetes and weight management.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide is a dual GLP-1/GIP receptor agonist administered as a once-weekly injection for type 2 diabetes and weight management. The SURMOUNT-1 trial demonstrated 22.5% weight loss with 15mg weekly dosing, but required extensive medical supervision due to significant gastrointestinal side effects.
  • Tirzepatide is administered once weekly, not multiple times daily as the video suggests
  • SURMOUNT-1 trial showed 22.5% weight loss with 15mg tirzepatide but required extensive medical supervision

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • Tirzepatide is administered once weekly, not multiple times daily as the video suggests
  • SURMOUNT-1 trial showed 22.5% weight loss with 15mg tirzepatide but required extensive medical supervision
  • 60-80% of trial participants experienced gastrointestinal side effects like nausea and vomiting
  • 7.1% of SURMOUNT-1 participants discontinued treatment due to adverse events
  • Legitimate tirzepatide requires prescription and medical screening, not social media discount codes
  • Clinical dosing starts at 2.5mg weekly and titrates up to 5mg, 10mg, or 15mg maintenance doses
  • The medication costs $900-1,200 monthly for branded versions without insurance coverage

Our take ยท Written by FormBlends editorial team ยท Reviewed by FormBlends Medical Team ยท This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

@rebekitaoficial jokingly says she'd take "Tirz" (tirzepatide) for "breakfast, lunch and dinner" if allowed, while promoting it with a discount code. The video treats the medication casually, like a lifestyle product rather than a prescription drug.

The creator doesn't make specific medical claims about tirzepatide's effects. But the casual tone and promotional discount code suggest she's treating this diabetes medication like a supplement you can order online.

This approach misses the mark entirely. Tirzepatide requires medical supervision, dosage titration, and isn't something you take multiple times daily.

Does the science support casual tirzepatide use?

Absolutely not. Tirzepatide is a once-weekly injection that requires careful medical monitoring. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed 22.5% weight loss with 15mg tirzepatide, but participants received extensive medical supervision.

The drug works by activating GLP-1 and GIP receptors to slow gastric emptying and reduce appetite. Taking it "for breakfast, lunch and dinner" would be medically dangerous and physiologically pointless.

Clinical trials started participants at 2.5mg weekly, gradually increasing to maintenance doses of 5mg, 10mg, or 15mg over months. The SURMOUNT studies required regular check-ins for side effects like nausea, vomiting, and diarrhea that affected 60-80% of participants.

What's wrong with this promotional approach?

Treating prescription medications like lifestyle products is problematic. The video's discount code promotion suggests you can simply purchase tirzepatide online without proper medical evaluation.

Real tirzepatide treatment involves screening for contraindications like diabetic retinopathy, thyroid cancer history, and pancreatitis risk. The FDA approval requires prescriber oversight because of potential serious side effects.

The casual "breakfast, lunch and dinner" joke trivializes a medication that can cause significant gastrointestinal side effects. In SURMOUNT-1, 7.1% of participants discontinued treatment due to adverse events, mostly related to nausea and vomiting.

What should you know about tirzepatide access?

Legitimate tirzepatide requires a prescription and medical supervision. The medication isn't available through social media discount codes or casual online purchases.

Branded tirzepatide (Mounjaro for diabetes, Zepbound for weight management) costs $900-1,200 monthly without insurance. Some telehealth platforms offer compounded versions at lower costs, but these still require medical consultations.

The SURMOUNT trials excluded people with eating disorders, certain psychiatric conditions, and multiple medical contraindications. A TikTok discount code can't replace proper medical screening that determines if you're a candidate for this medication.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

๐Ÿ’โœจ๐“ก๐“ฎ๐“ซ๐“ฎโœจ๐Ÿ’ ยท TikTok creator

432.6K views on this video

Tirz de desayuno,Almuerzo y Cena si me dejan ๐Ÿ˜‚. Comienza hoy con tu jornada y te ahorras 100 con el cรณdigo: PR #fridays #fyp #seguidores #viral #parati

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide?

Tirzepatide is administered once weekly, not multiple times daily as the video suggests

What does the video say about surmount-1 trial showed 22.5% weight loss with 15mg tirzepatide?

SURMOUNT-1 trial showed 22.5% weight loss with 15mg tirzepatide but required extensive medical supervision

What does the video say about 60-80% of trial participants experienced gastrointestinal side effects like nausea?

60-80% of trial participants experienced gastrointestinal side effects like nausea and vomiting

What does the video say about 7.1% of surmount-1 participants discontinued treatment due to adverse events?

7.1% of SURMOUNT-1 participants discontinued treatment due to adverse events

What does the video say about legitimate tirzepatide requires prescription?

Legitimate tirzepatide requires prescription and medical screening, not social media discount codes

What does the video say about clinical dosing starts at 2.5mg weekly?

Clinical dosing starts at 2.5mg weekly and titrates up to 5mg, 10mg, or 15mg maintenance doses

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by ๐Ÿ’โœจ๐“ก๐“ฎ๐“ซ๐“ฎโœจ๐Ÿ’, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.